| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 20th August 2020 | Bankole A. Johnson | 350,000 | Open or private sale | $1.21 | $423,500.00 |
| 27th March 2020 | James W. Jr. Newman | 5,000 | Open or private purchase | $1.42 | $7,100.00 |
| 27th March 2020 | James W. Jr. Newman | 10,000 | Open or private purchase | $1.34 | $13,400.00 |
| 27th March 2020 | James W. Jr. Newman | 4,644 | Open or private purchase | $1.35 | $6,269.40 |
| 26th March 2020 | William B. Iii Stilley | 12,652 | Open or private purchase | $1.47 | $18,598.44 |
| 25th March 2020 | William B. Iii Stilley | 12,348 | Open or private purchase | $1.13 | $13,953.24 |
| 3rd March 2020 | Joseph Truluck | 27,084 | Grant/award etc. | $0.00 | |
| 3rd March 2020 | William B. Iii Stilley | 54,167 | Grant/award etc. | $0.00 | |
| 12th December 2019 | Bankole A. Johnson | 150,000 | Open or private sale | $1.00 | $150,000.00 |
| 2nd October 2019 | Bankole A. Johnson | 3,187 | Grant/award etc. | $0.00 |
Adial Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial.
Ticker: ADIL
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1513525
Employees:
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial
25th February 2021
Adial to File Fast Track Application for AD04 with the FDA
23rd February 2021